GoalVest Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

GoalVest Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54	Closed	-$1.63K	–	557
2026 Q1	$1.63K	Hold	54	–	–	﹤0.01%	428
2025 Q4	$1.69K	Hold	54	–	–	﹤0.01%	495
2025 Q3	$1.09K	Hold	54	–	–	﹤0.01%	390
2025 Q2	$905	Hold	54	–	–	﹤0.01%	347
2025 Q1	$830	Buy	+54	New	+$965	﹤0.01%	342

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

GoalVest Advisory's TEVA Position: Q2 2026 in Review

GoalVest Advisory sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 54 shares — an estimated $1.63K sold.

GoalVest Advisory first reported a position in TEVA in Q1 2025 and held it in 5 quarters. The position peaked at $1.69K in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

GoalVest Advisory reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
GoalVest Advisory sold 54 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.63K.
GoalVest Advisory first reported a position in Teva Pharmaceuticals in Q1 2025 and held it in 5 quarters.
GoalVest Advisory's Teva Pharmaceuticals position peaked at $1.69K in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on GoalVest Advisory's 13F filing for Q2 2026, filed 9 Jul 2026.